aztreonam-avibactam
Selected indexed studies
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. (Lancet Infect Dis, 2025) [PMID:39389071]
- Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens. (Pharmacotherapy, 2024) [PMID:39601336]
- Aztreonam and Avibactam. (, 2006) [PMID:40127370]
_Worker-drafted node — pending editorial review._
Connections
aztreonam-avibactam is a side effect of
Sources
- Past, present, and future perspectives on aztreonam and avibactam. (2025) pubmed
- Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. (2025) pubmed
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. (2025) pubmed
- Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens. (2024) pubmed
- Aztreonam and Avibactam. (2006) pubmed
- Aztreonam and avibactam combination therapy for metallo-β-lactamase-producing gram-negative bacteria: A Narrative Review. (2025) pubmed
- Aztreonam-avibactam for the treatment of intra-abdominal infections. (2024) pubmed
- Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). (2025) pubmed
- The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. (2021) pubmed
- Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. (2024) pubmed